{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:59Z","timestamp":1793228279018,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Unrestricted grant"],"award-info":[{"award-number":["Unrestricted grant"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ard-2022-222784","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T13:20:45Z","timestamp":1660224045000},"page":"773-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02991469","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kastriot","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Voshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-0385","authenticated-orcid":false,"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd-R\u00fcdiger R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-8451","authenticated-orcid":false,"given":"Johannes WJ","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest H","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-2020","authenticated-orcid":false,"given":"Mary K","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-6354","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy M","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-724X","authenticated-orcid":false,"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7056","authenticated-orcid":false,"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":false,"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo F","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-1934","authenticated-orcid":false,"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Poor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-2833","authenticated-orcid":false,"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222784_bib1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard.2008.097683","article-title":"DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis","volume":"69","author":"Goekoop-Ruiterman","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16\u2005weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the idea study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/rheumatology\/ker399","article-title":"Goal-Directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years","volume":"51","author":"Gullick","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-222784_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1756-185X.12754","article-title":"APLAR rheumatoid arthritis treatment recommendations","volume":"18","author":"Lau","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ard.59.7.504","article-title":"Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis","volume":"59","author":"Smolen","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1136\/ard-2022-222784_bib15","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/annrheumdis-2012-202469","article-title":"Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib18","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-Phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1136\/ard-2022-222784_bib20","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1136\/ard-2022-222784_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"10.1136\/ard-2022-222784_bib22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1178334","article-title":"Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells","volume":"327","author":"O'Shea","year":"2010","journal-title":"Science"},{"key":"10.1136\/ard-2022-222784_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"Il-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1136\/ard-2022-222784_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"10.1136\/ard-2022-222784_bib25","first-page":"S11","article-title":"Interleukin-6\u2013a key mediator of systemic and local symptoms in rheumatoid arthritis","volume":"65","author":"Cronstein","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1136\/ard-2022-222784_bib26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"Il-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J Hepatol"},{"key":"10.1136\/ard-2022-222784_bib27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"Il-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-222784_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib29","doi-asserted-by":"crossref","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","article-title":"Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex","volume":"290","author":"Lacroix","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1136\/ard-2022-222784_bib30","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/j.1460-2075.1995.tb07186.x","article-title":"Two distinct and independent sites on IL-6 trigger GP 130 dimer formation and signalling","volume":"14","author":"Paonessa","year":"1995","journal-title":"Embo J"},{"key":"10.1136\/ard-2022-222784_bib31","author":"U.S.Food and Drug administration - Center for Drug Evaluation and Research"},{"key":"10.1136\/ard-2022-222784_bib32","author":"Creative biolabs"},{"key":"10.1136\/ard-2022-222784_bib33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1136\/ard-2022-222784_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2022-222784_bib35","first-page":"259","article-title":"Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody","volume":"20","author":"Wendling","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib37","unstructured":"Oxford Center for Evidence Based Medicine. Levels of evidence; 2009."},{"key":"10.1136\/ard-2022-222784_bib38","article-title":"SLR for updated IL-6 consensus statement","author":"Kastrati","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib39","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib40","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review Informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib42","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib43","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222784_bib44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2020-217209","article-title":"Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study","volume":"80","author":"Pappas","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222784_bib48","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222784_bib49","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib50","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib51","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-016-1108-9","article-title":"Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials","volume":"18","author":"Teitsma","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib53","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1136\/ard-2022-222784_bib55","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib56","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib57","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib58","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.41528","article-title":"Efficacy and safety of tocilizumab for Polyarticular-Course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib60","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1093\/rheumatology\/keab047","article-title":"Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib61","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib62","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib63","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib64","author":"Chugai Pharmaceutical Company"},{"key":"10.1136\/ard-2022-222784_bib65","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib67","article-title":"Tocilizumab for giant cell arteritis","volume":"8","author":"Antonio","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ard-2022-222784_bib68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib69","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1136\/ard-2022-222784_bib71","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1136\/ard-2022-222784_bib72","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ard-2022-222784_bib73","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2040620716653745","article-title":"Review of siltuximab in the treatment of multicentric Castleman's disease","volume":"7","author":"Sarosiek","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1136\/ard-2022-222784_bib74","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib75","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1136\/ard-2022-222784_bib76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","article-title":"Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Efficacy and safety of tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE) - a phase 3 randomized controlled trial","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib80","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2022-222784_bib81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1852","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. double-blind, placebo-controlled, International study (ALIGN)","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib83","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of Clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib84","first-page":"251","article-title":"Off-Label use of tocilizumab in psoriatic arthritis: case series and review of the literature","volume":"41","author":"Madureira","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"10.1136\/ard-2022-222784_bib85","doi-asserted-by":"crossref","first-page":"329-338","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib86","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib87","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib88","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-222784_bib89","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","article-title":"Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib90","doi-asserted-by":"crossref","first-page":"21522","DOI":"10.1038\/s41598-021-00726-4","article-title":"Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis","volume":"11","author":"Malgie","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2022-222784_bib91","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222784_bib92","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib93","author":"World Health Organization"},{"key":"10.1136\/ard-2022-222784_bib94","author":"U.S.Food and Drug Administration"},{"key":"10.1136\/ard-2022-222784_bib95","author":"European Medicines Agency"},{"key":"10.1136\/ard-2022-222784_bib96","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","article-title":"Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis","volume":"40","author":"Shimamoto","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/14397595.2013.854079","article-title":"Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study","volume":"24","author":"Nishimoto","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib98","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib99","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.41299","article-title":"Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating Sarilumab from adalimumab or methotrexate in a post hoc analysis","volume":"72","author":"Boyapati","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib101","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/annrheumdis-2020-eular.4164","article-title":"The effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid arthritis","volume":"79","author":"Davies","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001290","article-title":"Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT","volume":"6","author":"Sch\u00e4fer","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib103","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","article-title":"Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register","volume":"54","author":"Forsblad-d'Elia","year":"2015","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib104","first-page":"A725","article-title":"Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months","volume":"78","author":"Saraux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","article-title":"Real-World persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic","volume":"7","author":"Best","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-222784_bib106","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","article-title":"Patient-Reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib107","doi-asserted-by":"crossref","first-page":"e000416","DOI":"10.1136\/rmdopen-2016-000416","article-title":"Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response\/intolerance to tumour necrosis factor inhibitors","volume":"3","author":"Strand","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib108","doi-asserted-by":"crossref","first-page":"e000602","DOI":"10.1136\/rmdopen-2017-000602","article-title":"Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis","volume":"4","author":"Strand","year":"2018","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib109","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00296-020-04596-3","article-title":"Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study","volume":"40","author":"Ayaz","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-222784_bib110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib111","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-Term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib112","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-222784_bib113","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/L19-0528","article-title":"Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty","volume":"171","author":"George","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-222784_bib114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial","volume":"396","author":"Burmester","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","article-title":"Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib116","article-title":"New-Onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension","author":"Stone","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib117","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40801-015-0018-5","article-title":"Comparison of healthcare costs between rheumatoid arthritis patients treated with infused biologics after switching from another biologic","volume":"2","author":"Johnston","year":"2015","journal-title":"Drugs Real World Outcomes"},{"key":"10.1136\/ard-2022-222784_bib118","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3111\/13696998.2011.649327","article-title":"Cost-Effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis","volume":"15","author":"Soini","year":"2012","journal-title":"J Med Econ"},{"key":"10.1136\/ard-2022-222784_bib119","article-title":"Is tocilizumab monotherapy as effective in preventing radiographic progression in rheumatoid arthritis as its combination with methotrexate?","author":"Verhoeven","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222784_bib120","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s12325-019-00946-1","article-title":"Economic evaluation of Sarilumab in the treatment of adult patients with Moderately-to-Severely active rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"36","author":"Muszbek","year":"2019","journal-title":"Adv Ther"},{"key":"10.1136\/ard-2022-222784_bib121","unstructured":"European Medicines Agency. RoActemra-Summary of product characteristics. [Last accessed April 29th, 2012]. 2009. Ref Type: Grant."},{"key":"10.1136\/ard-2022-222784_bib122","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar4127","article-title":"Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib123","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"72","author":"Mori","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib124","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/14397595.2013.843743","article-title":"Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab","volume":"24","author":"Tsuru","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib126","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib127","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib128","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib129","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/annrheumdis-2020-219724","article-title":"EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19","volume":"80","author":"Alunno","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib131","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib132","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib133","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gr\u00f8n","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib134","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-World comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib135","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib136","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib137","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib138","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-Term safety and efficacy of tocilizumab in early systemic Sclerosis-Interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard-2022-222784_bib139","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ard-2022-222784_bib140","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib141","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib142","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jcrc.2021.10.020","article-title":"COVID 19 and the risk of gastro-intestinal perforation: a case series and literature review","volume":"67","author":"Bulte","year":"2022","journal-title":"J Crit Care"},{"key":"10.1136\/ard-2022-222784_bib143","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib144","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib145","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib146","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semarthrit.2017.08.001","article-title":"Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: new evidence from real-world data","volume":"47","author":"Paul","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib147","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semarthrit.2008.01.006","article-title":"Role of interleukin-6 in the anemia of chronic disease","volume":"38","author":"Raj","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib148","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib149","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-Blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib150","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib151","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","article-title":"Long-Term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry","volume":"59","author":"Klein","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib152","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib153","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","article-title":"No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study","volume":"48","author":"Kim","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib154","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a Multi-Database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/acr.23737","article-title":"Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients","volume":"71","author":"Xie","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222784_bib156","doi-asserted-by":"crossref","first-page":"rkaa027","DOI":"10.1093\/rap\/rkaa027","article-title":"Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus","volume":"4","author":"Chen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2022-222784_bib157","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-020-02229-5","article-title":"Interleukin-6 receptor blockade or TNF\u03b1 inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib158","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2014-206695","article-title":"Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)","volume":"74","author":"Mori","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib159","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222784_bib160","first-page":"2306","article-title":"No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab","volume":"71","author":"Strangfeld","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222784_bib161","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1136\/ard-2022-222784_bib162","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00198-020-05488-9","article-title":"Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study","volume":"31","author":"Shin","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard-2022-222784_bib163","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","article-title":"The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis","volume":"53","author":"Kume","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib164","doi-asserted-by":"crossref","first-page":"e0188454","DOI":"10.1371\/journal.pone.0188454","article-title":"Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-222784_bib165","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keab355","article-title":"Long-Term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors","volume":"60","author":"Fleischmann","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib166","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","article-title":"Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study","volume":"389","author":"Aletaha","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222784_bib167","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1136\/annrheumdis-2017-211328","article-title":"Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study","volume":"76","author":"Takeuchi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib168","doi-asserted-by":"crossref","first-page":"e000731","DOI":"10.1136\/rmdopen-2018-000731","article-title":"Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study","volume":"4","author":"Thorne","year":"2018","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001465","article-title":"Long-Term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)","volume":"7","author":"Aletaha","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222784_bib170","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/acr.23141","article-title":"Risk of hypersensitivity to biologic agents among Medicare patients with rheumatoid arthritis","volume":"69","author":"Yun","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222784_bib171","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222784_bib172","author":"Food and Drug Administration U"},{"key":"10.1136\/ard-2022-222784_bib173","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222784_bib174","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pds.4930","article-title":"Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden","volume":"29","author":"Br\u00f6ms","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2022-222784_bib175","article-title":"Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis","author":"Hellgren","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222784_bib176","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724083900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T18:27:50Z","timestamp":1737224870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724083900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":176,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0003496724083900"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222784","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}